Information Provided By:
Fly News Breaks for August 11, 2016
VSAR
Aug 11, 2016 | 06:57 EDT
Citi analyst Yigal Nochomovitz raised his price target for Versartis to $23 saying the company's partnership with Teijin for commercialization of somavaratan in Japan validates the drug's clinical profile. The economics of the deal are very favorable for Versartis, Nochomovitz tells investors in a research note. He keeps a Buy rating on the shares.
News For VSAR From the Last 2 Days
There are no results for your query VSAR